BioRestorative Therapies, Inc. (NASDAQ:BRTX) Sees Large Growth in Short Interest

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 715,900 shares, an increase of 205.8% from the February 13th total of 234,100 shares. Currently, 14.3% of the company’s stock are short sold. Based on an average trading volume of 390,000 shares, the short-interest ratio is presently 1.8 days.

Hedge Funds Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. Citadel Advisors LLC acquired a new position in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned approximately 0.31% of BioRestorative Therapies as of its most recent filing with the SEC. Institutional investors and hedge funds own 69.38% of the company’s stock.

BioRestorative Therapies Stock Up 0.3 %

NASDAQ:BRTX opened at $1.60 on Thursday. The company has a fifty day simple moving average of $1.96 and a two-hundred day simple moving average of $1.71. The company has a market cap of $11.07 million, a price-to-earnings ratio of -1.05 and a beta of 64.37. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $2.55.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.